Abstract:Adenosine is an evolutionary ancient metabolic regulator linking energy state to physiologic processes, including immunomodulation and cell proliferation. Tumors create an adenosine-rich immunosuppressive microenvironment through the increased release of ATP from dying and stressed cells and its ectoenzymatic conversion into adenosine. Therefore, the adenosine pathway becomes an important therapeutic target to improve the effectiveness of immune therapies. Prior research has focused largely on the two major ectonucleotidases, ectonucleoside triphosphate diphosphohydrolase 1/cluster of differentiation (CD)39 and ecto-5'-nucleotidase/CD73, which catalyze the breakdown of extracellular ATP into adenosine, and on the subsequent activation of different subtypes of adenosine receptors with mixed findings of antitumor and protumor effects. New findings, needed for more effective therapeutic approaches, require consideration of redundant pathways controlling intratumoral adenosine levels, including the alternative NAD-inactivating pathway through the CD38-ectonucleotide pyrophosphatase phosphodiesterase (ENPP)1-CD73 axis, the counteracting ATP-regenerating ectoenzymatic pathway, and cellular adenosine uptake and its phosphorylation by adenosine kinase. This review provides a holistic view of extracellular and intracellular adenosine metabolism as an integrated complex network and summarizes recent data on the underlying mechanisms through which adenosine and its precursors ATP and ADP control cancer immunosurveillance, tumor angiogenesis, lymphangiogenesis, cancer-associated thrombosis, blood flow, and tumor perfusion. Special attention is given to differences and commonalities in the purinome of different cancers, heterogeneity of the tumor microenvironment, subcellular compartmentalization of the adenosine system, and novel roles of purine-converting enzymes as targets for cancer therapy. Significance Statement The discovery of the role of adenosine as immune checkpoint regulator in cancer has led to the development of novel therapeutic strategies targeting extracellular adenosine metabolism and signaling in multiple clinical trials and preclinical models. Here we identify major gaps in knowledge that need to be filled to improve the therapeutic gain from agents targeting key components of the adenosine metabolic network and, on this basis, provide a holistic view of the cancer purinome as a complex and integrated network.

Exploring the Multifaceted Role of Adenosine Nucleotide Translocase 2 in Cellular and Disease Processes: A Comprehensive Review.

Adenine nucleotide translocase: Current knowledge in post-translational modifications, regulations and pathological implications for human diseases

ANTs and cancer: Emerging pathogenesis, mechanisms, and perspectives

Tumor-Promoting ATAD2 and Its Preclinical Challenges

ANT2 functions as a translocon for mitochondrial cross-membrane translocation of RNAs

The ADP/ATP Translocase Drives Mitophagy Independent of Nucleotide Exchange.

From Cellular Functions to Therapeutic Potentials

Depletion of Toxoplasma adenine nucleotide translocator leads to defects in mitochondrial morphology

Adenine nucleotide (ADP/ATP) translocase 3 participates in the tumor necrosis factor induced apoptosis of MCF-7 cells.

NMNAT2: an Important Metabolic Enzyme Affecting the Disease Progression

Regulation of Mitochondrial Respiratory Chain Complex Levels, Organization, and Function by Arginyltransferase 1

0256: A Screening Strategy to Identify Modulators of the Mitochondrial ADP/ATP Translocase (ANT) for Cardioprotection

Mitochondrial ATP transporter Ant2 depletion impairs erythropoiesis and B lymphopoiesis

ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain

Limiting mitochondrial-derived ATP transfer to the cytosol enhances T-cell activation

The Expression of Adenine Nucleotide Translocator in Myocardium under Pressure Load in Rats

The key role of the NAD biosynthetic enzyme nicotinamide mononucleotide adenylyltransferase in regulating cell functions

The adenine nucleotide translocase family underlies cardiac ischemia-reperfusion injury through the mitochondrial permeability pore independently of cyclophilin D

Molecular and metabolic landscape of adenosine triphosphate-induced cell death in cardiovascular disease

The rate of ATP export in the extramitochondrial phase via the adenine nucleotide translocator changes in aging in mitochondria isolated from heart left ventricle of either normotensive or spontaneously hypertensive rats

The Immune Regulatory Role of Adenosine in the Tumor Microenvironment